lynda

Frontier Pharma-Obesity Identifying and Commercializing Pipeline Product Innovation

Press Release   •   Dec 22, 2015 07:55 EST

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients. However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect. Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.

Complete report on “Frontier Pharma: Obesity” addition with 02 market data tables and 45 figures, spread across 87 pages ishttp://www.rnrmarketresearch.com/frontier-pharma-obesity-identifying-and-commercializing-first-in-class-innovation-market-report.html .

Scope:

  • Why is sustainable weight loss difficult to achieve, and what is the implication for future drug development?
  • What is the dominant target family across these first-in-class pipeline products?
  • How well do they align with the underlying signaling pathways governing the central and peripheral regulation of food intake, and energy expenditure?
  • What is the scientific rationale behind these targets? How are they likely to surpass existing treatment?
  • Apart from body weight change, what other parameters are commonly used to measure the effect of investigational therapies?
  • What is the dominant molecular target in the obesity deals landscape?
  • What are the promising first-in-class products still available for future licensing?

Request for sample:
http://www.rnrmarketresearch.com/contacts/request-sample?rname=437610 . (This is a premium report price at US$6995 for a single user PDF license)

Reasons to buy:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the available treatment options and their limitations in terms of safety and efficacy.
  • Visualize the composition of the obesity market to highlight the current unmet needs in order to gain a competitive understanding of the key opportunities.
  • Analyze the obesity pipeline and stratify by stage of development, molecule type, and molecular target; the diversity of molecular targets in the pipeline is extremely encouraging as obesity is characterized by the complex interplay between central and peripheral mechanisms.
  • Assess the therapeutic potential of first-in-class targets using a proprietary matrix that assesses and ranks first-in-class products according to clinical potential.
  • Target the most promising and innovative obesity products for early-stage investment by analyzing trends in licensing and co-development deals and accessing a curated list of first-in-class therapies potentially open to deal-making opportunities.

Explore More Research Report on Diseases & treatment Market.

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries